Literature DB >> 32014969

Preoperative Survival Prediction in Patients With Glioblastoma by Routine Inflammatory Laboratory Parameters.

Daniela Pierscianek1,2, Yahya Ahmadipour3,2, Anna Michel3,2, Mehdi Chihi3,2, Marvin Darkwah Oppong3,2, Sied Kebir2,4, Martin Glas2,4, Martin Stuschke2,5, Ulrich Sure3,2, Ramazan Jabbarli3,2.   

Abstract

BACKGROUND: Glioblastoma (GBM) is the most common malignant brain tumor in adults and still carries a dismal prognosis. As several studies detected a connection between inflammation and GBM prognosis, we sought to explore possible associations between routinely investigated inflammatory parameters and GBM outcome. PATIENTS AND METHODS: Patients treated for GBM at our Institution between 2004 and 2014 were included. White blood cell count (WBC), C-reactive protein (CRP) and the ratio of platelets and WBC (Plt/WBC) were evaluated preoperatively. Medical records were reviewed for clinical parameters (age, sex, preoperative clinical condition, genetic alterations). Study endpoints were overall (OS) and 1- and 2-year survival.
RESULTS: In the final cohort consisting of 565 individuals with GBM, univariate analysis showed significant associations for WBC, CRP and Plt/WBC ratio with OS. Kaplan-Meier survival plot confirmed significantly poorer OS in patients with WBC>12/nl and with CRP≥2.9 mg/dl. In multivariate analysis, a WBC of >12/nl was an independent prognostic factor for all three outcome parameters and CRP≥2.9 mg/dl for OS and 1-year survival.
CONCLUSION: Preoperative WBC and CRP values were confirmed as independent predictors of GBM outcome. This emphasizes the need for further evaluation of the role of inflammation in the prognosis of GBM. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Glioblastoma; inflammation; routine laboratory parameter

Mesh:

Substances:

Year:  2020        PMID: 32014969     DOI: 10.21873/anticanres.14058

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Targeted Genomic Sequencing Reveals Different Evolutionary Patterns Between Locally and Distally Recurrent Glioblastomas.

Authors:  Nara Yoon; Hyun-Soo Kim; Jung Whee Lee; Eui-Jin Lee; Lee-So Maeng; Wan Soo Yoon
Journal:  Cancer Genomics Proteomics       Date:  2020 Nov-Dec       Impact factor: 4.069

2.  Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide.

Authors:  Erkan Topkan; Ali A Besen; Huseyin Mertsoylu; Ahmet Kucuk; Berrin Pehlivan; Ugur Selek
Journal:  Int J Inflam       Date:  2020-06-08

3.  Prognostic Value of Preoperative Inflammatory Markers in Melanoma Patients with Brain Metastases.

Authors:  Matthias Schneider; Niklas Schäfer; Christian Bode; Valeri Borger; Lars Eichhorn; Frank A Giordano; Erdem Güresir; Muriel Heimann; Yon-Dschun Ko; Felix Lehmann; Anna-Laura Potthoff; Alexander Radbruch; Christina Schaub; Katjana S Schwab; Johannes Weller; Hartmut Vatter; Ulrich Herrlinger; Jennifer Landsberg; Patrick Schuss
Journal:  J Clin Med       Date:  2021-02-07       Impact factor: 4.241

4.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

5.  Early Pulmonary Metastasis After a Surgical Resection of Glioblastoma Multiforme. A Case Report.

Authors:  Killen H Briones-Claudett; Mónica H Briones-Claudett; Freddy Villacrés Garcia; Camilo Ortega Almeida; Andrea Escudero-Requena; Jaime Benítez Solís; Killen H Briones Zamora; Diana C Briones Márquez; Michelle Grunauer
Journal:  Am J Case Rep       Date:  2020-07-31

6.  Red blood cell distribution width to platelet ratio substantiates preoperative survival prediction in patients with newly-diagnosed glioblastoma.

Authors:  Matthias Schneider; Niklas Schäfer; Stefanos Apallas; Anna-Laura Potthoff; Christian Bode; Erdem Güresir; Muriel Heimann; Felix Lehmann; Elisa Scharnböck; Christina Schaub; Hartmut Vatter; Ulrich Herrlinger; Patrick Schuss
Journal:  J Neurooncol       Date:  2021-08-04       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.